Real-world impact of ivacaftor in people with cystic fibrosis and select ivacaftor-responsive mutations.

Abstract excerpt

BACKGROUND: Ivacaftor approval was extended to people with cystic fibrosis (CF) with ≥1 of 28 additional ivacaftor-responsive mutations in the USA in 2017 based on preclinical in vitro data. This retrospective, observational study assessed real-world clinical response to ivacaftor in people with CF with ≥1 of these mutations, using data from the US Cystic Fibrosis Foundation Patient Registry. METHODS:...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aminophenols
• Share to Chloride Channel Agonists
• Share to Cystic Fibrosis